Mimix OncoSpan Reference Control Panel
Bring comprehensive controls to your cancer assay with the Mimix OncoSpan panel.
Mimix Geni Somatic Cancer Reference Standards
Highly characterized reference materials for oncology NGS validation
The Mimix™ Geni™ reference standards are highly characterized controls developed in collaboration with the Medical Device Innovation Consortium (MDIC). They’ve been developed as part of the Somatic Reference Samples (SRS) Initiative to help clinical diagnostic labs improve the accuracy of their cancer diagnostic assays and medical device manufacturers verify their tests and platforms.
Mimix Geni reference standards
-
Mimix™ Geni™ Onco Mix 1 DNA/RNA FFPE Reference Standard
The Mimix™ Geni™ Onco Mix 1 DNA/RNA FFPE Reference Standard is an industry first pan-cancer dual DNA/RNA reference material.
-
Mimix™ Geni™ Negative FFPE Reference Standard
The Mimix™ Geni™ Negative FFPE Reference Standard is a negative control for the Mimix Geni Onco Mix 1 DNA/RNA FFPE Reference Standard (HD852).
-
Mimix™ Geni™ Onco Mix 1 DNA/RNA FFPE Reference Standard IVD
The Mimix™ Geni™ Onco Mix 1 DNA/RNA FFPE Reference Standard IVD is a pan-cancer dual DNA/RNA reference material developed with MDIC.
-
Mimix™ Geni™ Negative FFPE Reference Standard IVD
The Mimix™ Geni™ Negative FFPE Reference Standard IVD is a negative control for the Mimix Geni Onco Mix 1 DNA/RNA FFPE Reference Standard IVD.
Key Features
-
Built on Genome-in-a-Bottle Cell Line
These somatic reference standards are developed from the extensively tested and characterized Genome-in-a-Bottle Consortium (GIAB) cell line.
-
Expertly Engineered by Gene Editing Specialists
Revvity (then Horizon) was selected to join the SRS initiative for our gene editing and reference standard expertise as a development collaborator. Drawing from these expertise, we have successfully engineered the GIAB cell line to contain clinically-relevant cancer mutations selected by SRS steering committee experts.
-
Rigorous Validation
MDIC has rigorously tested and validated the Mimix Geni standards, with ongoing interlab validation.
-
Reliable Pan-Cancer Control Material
- Pan-cancer control material containing DNA and RNA fusions
- Generated from a GIAB Consortium cell line (GM24385)
- Engineered by Revvity with cancer mutations selected by industry experts
- Rigorous testing and validation by MDIC
-
Benefits for Oncology Diagnostic Labs
These highly characterized reference standards provide a robust foundation for assessing assay:
- Sensitivity
- Specificity
- Reproducibility
Development Timeline
Setting the Standard in Oncology NGS Reference Materials
Take a walk with us through the timeline behind the development of the Mimix Geni somatic cancer reference standards.
2011: Identifying the Challenge
The CDC convened leading experts to help integrate NGS into clinical testing. A critical gap emerged: the absence of a universally accepted reference sample for validating NGS workflows.
2012: Establishing Guidelines
The Next-generation Sequencing: Standardization of Clinical Testing workgroup published foundational guidelines, laying the groundwork for reliable, clinically actionable NGS results.
GIAB Consortium Established
To address the need for gold-standard reference materials, the Genome in a Bottle (GIAB) consortium was launched, producing highly characterized cell lines that are now globally recognized benchmarks.
However, oncology-specific reference materials remained elusive. Recognizing this gap, the MDIC convened the Somatic Reference Samples (SRS) Initiative, a public-private partnership to guide the development of reference samples that can be used to develop and validate NGS-based cancer diagnostics.
2020: Strategic Partnership
MDIC approached Revvity (then Horizon) for our gene editing and reference standard development expertise and, following our selection through an RFP process, a collaboration was formed.
2025: Breakthrough innovation
After years of co-development, we achieved a breakthrough: the first and only GIAB Consortium cell line engineered to contain seven clinically relevant oncology mutations as selected by the SRS steering committee of industry experts.
The result
Mimix Geni reference standards set a new benchmark for cancer diagnostics and NGS validation, providing the oncology community with trusted, characterized reference materials.
Explore resources and solutions
Carousel items
-
Enhancing NGS precision with Mimix Geni standards
This technical note describes the methods used to develop the Mimix Geni Onco Mix 1 DNA/RNA Reference Standard and the results of the verification. -
Browse all our reference standards.
Use the filter options to select your chosen format, analysis technique and/or sample type. -
Why cell line-derived?
This white paper examines why using cell line-derived reference material is critical for reliable genetic testing in oncology.
Related products
Mimix Pan-Cancer 6-Fusion Panel Reference Standard
Defined FFPE control material containing 6 clinically-relevant, cell-based kinase fusion RNA biomarkers.
Mimix Structural Multiplex Reference Standard
The Mimix Structural Multiplex FFPE Reference Standard is a highly-characterized, biologically-relevant quality control material.
For research use only. Not for use in diagnostic procedures.